<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Biology of warfarin and modulators of INR control</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Biology of warfarin and modulators of INR control</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Biology of warfarin and modulators of INR control</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell D Hull, MBBS, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Garcia, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara R Vazquez, PharmD, BCPS, CACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> and other vitamin K antagonists (VKAs, also called coumarins; eg, <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a>, phenprocoumon, fluindione) are used in a variety of clinical settings. Use of VKAs is challenging because their therapeutic range is narrow and dosing is affected by many factors including drug interactions, diet, and genetic variation in warfarin and vitamin K metabolism. Time spent with a prothrombin time/international normalized ratio (PT/INR) above the therapeutic range increases the risk of bleeding, and time spent below the therapeutic range increases the risk of thromboembolic complications.</p><p>This topic review discusses the biology, mechanism of action, and factors that modulate INR control during anticoagulation with a VKA.</p><p><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> administration, and management of warfarin-associated bleeding and supratherapeutic INR, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p class="headingAnchor" id="H173534056"><span class="h1">BIOLOGY</span></p><p class="headingAnchor" id="H445860"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> and related vitamin K antagonists (VKAs) block the function of the vitamin K epoxide reductase complex in the liver, leading to depletion of the reduced form of vitamin K that serves as a cofactor for gamma carboxylation of vitamin K-dependent coagulation factors [<a href="#rid1">1</a>]. The epoxide reductase is needed to recycle vitamin K between reduced and epoxide forms. Without gamma carboxylation, the vitamin K-dependent factors, including factors II (prothrombin), VII, IX, and X, are immunologically detectable, but they cannot function because they cannot adequately bind calcium and phospholipid membranes needed for their hemostatic function [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.)</p><p>Gamma carboxylation of glutamic acid residues occurs at the time of protein synthesis; it does not affect the structure or function of existing proteins. Thus, the ultimate anticoagulant effect of VKAs is delayed until the previously synthesized, functional clotting factors are cleared from the circulation. Depletion of both factor X and factor II (prothrombin) is important for clinical efficacy, and factor II has the longest half-life of the vitamin K-dependent factors (approximately three days) [<a href="#rid3">3,4</a>]. Thus, the desired anticoagulant effect of a VKA does not occur for at least three days after drug initiation despite prolongation of the prothrombin time (PT) at earlier time points. The initial prolongation of the PT is due primarily to depletion of factor VII, which has a short half-life (four to six hours)  (<a class="graphic graphic_figure graphicRef50940" href="/d/graphic/50940.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]. (See <a class="local">'PT/INR prolongation'</a> below.)</p><p>VKAs also inhibit vitamin K-dependent gamma carboxylation of the anticoagulant factors protein S and protein C, which inhibit activated factors VIII and V. Thus, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> has a transient procoagulant effect during the first day or two of use. This is rarely of clinical significance, with the possible exception of patients who receive "loading doses" of warfarin (especially those with inherited protein C deficiency) who may (rarely) develop warfarin-induced skin necrosis [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/1354.html" rel="external">"Protein C deficiency", section on 'Warfarin-induced skin necrosis'</a>.)</p><p>Administration of large doses of vitamin K1 can render patients resistant to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for up to a week or more. The vitamin K accumulates in the liver and bypasses the need for vitamin K recycling by the epoxide reductase [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1163176"><span class="h2">PT/INR prolongation</span><span class="headingEndMark"> — </span>At therapeutic levels of anticoagulation, VKAs prolong the PT, which reflects the extrinsic pathway of coagulation in vitro  (<a class="graphic graphic_figure graphicRef79998" href="/d/graphic/79998.html" rel="external">figure 2</a>). Most laboratories and portable devices report the results of the PT along with an INR, a parameter that allows comparison of PT values from different institutions. PT readings from different institutions cannot be accurately compared, because different laboratories often use different assay reagents that could produce different PT readings for the same plasma sample. The INR standardizes the PT value to an international reference thromboplastin standard. The three reference standards in use are thromboplastin made from recombinant human tissue factor reconstituted into phospholipid vesicles, or thromboplastin from rabbit or bovine (cow) origin [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Prothrombin time (PT) and INR'</a>.)</p><p>The initial prolongation of the PT/INR during the first one to three days of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> initiation does not reflect full anticoagulation, because only the factor with the shortest half-life (factor VII, half-life four to six hours) is initially depleted  (<a class="graphic graphic_table graphicRef51595" href="/d/graphic/51595.html" rel="external">table 1</a>); other functional vitamin K-dependent factors with longer half-lives (eg, prothrombin, half-life approximately three days) continue to circulate [<a href="#rid5">5</a>] (see <a class="local">'Mechanism of action'</a> above). The full anticoagulant effect of a VKA generally occurs within approximately one week after the initiation of therapy and results in equilibrium levels of functional factors II, IX, and X at approximately 10 to 35 percent of normal [<a href="#rid3">3</a>].</p><p>The clinical implications of the delay in full anticoagulation were demonstrated in a trial that compared treatment with a VKA alone or a VKA overlapped with intravenous heparin in patients with an acute proximal deep vein thrombosis (DVT) [<a href="#rid9">9</a>]. The trial was terminated early (after accrual of 120 patients) due to an excess of symptomatic thromboembolic events in the VKA alone group. This delay in full anticoagulation despite prolongation of the PT/INR during initial therapy provides the rationale for overlapping another anticoagulant such as a parenteral agent with a VKA during the initial days of therapy (so called "bridging") in patients with an especially high thromboembolic risk. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Transitioning between anticoagulants/bridging'</a> and  <a class="medical medical_review" href="/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Transition to warfarin or other outpatient anticoagulant'</a> and  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Limited indications for bridging'</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at low risk of bleeding'</a>.)</p><p>For patients who are stably anticoagulated with a VKA, the percentage of time in the therapeutic range (TTR) is often used as a measure of the quality of anticoagulation control. At a conference on anticoagulation, approximately three-quarters of the 250 participants reported using a TTR measure as a quality indicator for their anticoagulation services [<a href="#rid10">10</a>]. TTR can be calculated using a variety of methods (eg, linear interpolation between INR values; percent of INRs in range, cross section of in-range INRs at a single time point) [<a href="#rid11">11</a>]. The TTR reported depends on the method of calculation as well as the INR range considered "therapeutic." A TTR of 65 to 70 percent is considered to be a reasonable and achievable degree of INR control in most settings [<a href="#rid10">10,11</a>]. The effect of various practice settings on TTR and the correlation between INR control and clinical outcomes are discussed separately. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Importance of strict INR control'</a>.)</p><p>At levels of therapeutic anticoagulation, VKAs typically cause only mild prolongation (or do not prolong) the activated partial thromboplastin time (aPTT), and they do not prolong the anti-factor Xa activity level, a test typically used to measure the effect of heparin or direct oral factor Xa inhibitors  (<a class="graphic graphic_table graphicRef91267" href="/d/graphic/91267.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Patient on anticoagulant'</a>.)</p><p class="headingAnchor" id="H446086"><span class="h2">VKA metabolism</span><span class="headingEndMark"> — </span>VKAs are absorbed via the gastrointestinal tract, circulate bound to albumin, and accumulate in the liver. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> reaches maximal blood concentrations approximately 90 minutes after oral administration; only the non-protein-bound fraction is biologically active.</p><p>Commercially available <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a> are racemic mixtures of S and R enantiomers. S-warfarin is more potent than R-warfarin. S-warfarin is metabolized primarily by the hepatic cytochrome P-450 2C9 isoform (CYP2C9); R-warfarin also undergoes a small degree of hepatic metabolism by other P-450 cytochromes (eg, 1A2, 3A4) and is excreted in the urine [<a href="#rid12">12</a>]. Thus, the overall anticoagulant effect of warfarin is more likely to be influenced by <em>CYP2C9</em> genotype and CYP2C9 drug interactions (eg, medications, over-the-counter herbal remedies) than by <em>CYP1A2/CYP3A4</em> genotype or other drug interactions [<a href="#rid13">13</a>]. However, the relative importance of the S versus the R enantiomer may vary among patients depending on patient comorbidities, medications, and genetic factors (see <a class="local">'Comorbidities'</a> below and <a class="local">'Drug interactions'</a> below and <a class="local">'Genetic factors'</a> below). Phenprocoumon is also metabolized by CYP2C9, but levels appear to be less influenced by <em>CYP2C9</em> genotype.</p><p>Tecarfarin (ATI-5923) is a VKA in development that is not affected by the CYP2C9 system; it is metabolized by esterases rather than CYPs [<a href="#rid14">14</a>]. Accordingly, it is not susceptible to many of the genetic and medication effects common to the other VKAs. However, in a 2016 trial that randomly assigned 607 individuals who required anticoagulation to receive tecarfarin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, the TTR was similar between the two drugs, even in patients who were receiving CYP2C9-interacting drugs, suggesting that this potential benefit may not be clinically relevant [<a href="#rid15">15</a>].</p><p>VKAs differ in their half-lives:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> – 36 to 42 hours (slightly less than two days) [<a href="#rid5">5,13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">Acenocoumarol</a> – 8 to 11 hours [<a href="#rid13">13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenprocoumon</strong> – three to five days or longer [<a href="#rid13">13,16</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluindione</strong> – 69 hours (slightly less than three days) [<a href="#rid17">17</a>]</p><p></p><p>A variety of environmental and genetic factors further influence the absorption, pharmacokinetics, and pharmacodynamics of the VKAs, leading to great inter- and intra-patient variability in anticoagulant response. (See <a class="local">'Drug interactions'</a> below and <a class="local">'Comorbidities'</a> below and <a class="local">'Genetic factors'</a> below.)</p><p class="headingAnchor" id="H85119"><span class="h2">Teratogenicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is a teratogen. Evidence regarding the specific embryopathic events and their mechanisms are presented separately. (See  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a> and  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Warfarin teratogenicity'</a>.)</p><p>However, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is not detected in human breast milk. Breastfeeding is reasonable as long as the infant is monitored for bruising and bleeding [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H1164785"><span class="h1">OVERVIEW OF INR CONTROL</span></p><p class="headingAnchor" id="H425848790"><span class="h2">Summary of factors that affect INR control</span><span class="headingEndMark"> — </span>A variety of factors influence <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose requirement, including genetic and environmental influences. Patients receiving warfarin should attempt to keep dietary vitamin K intake relatively constant over time to minimize the risk of under- or over-anticoagulation (eg, subtherapeutic INR with increased vitamin K intake or supratherapeutic INR with decreased vitamin K intake). More frequent monitoring of the prothrombin time (PT)/INR is used to guide VKA dose modifications in the presence of interacting medications to reduce the risk of over- or under-anticoagulation. An advantage of warfarin is that the INR can be monitored and the warfarin dose can be adjusted to account for changes in diet or other medications. (See <a class="local">'Risk factors for supratherapeutic INR'</a> below and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Monitoring (PT/INR)'</a>.)</p><p>Factors that affect the dose-response relationship between <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose and INR include the following [<a href="#rid1">1,12,20-24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional status, including vitamin K intake</p><p class="bulletIndent1"><span class="glyph">●</span>Medication adherence</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic variation</p><p class="bulletIndent1"><span class="glyph">●</span>Drug interactions</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking and alcohol use</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney, liver, and cardiac function</p><p class="bulletIndent1"><span class="glyph">●</span>Hypermetabolic states</p><p></p><p>These are discussed in more detail in the sections below.</p><p class="headingAnchor" id="H2657492899"><span class="h2">Risk factors for supratherapeutic INR</span><span class="headingEndMark"> — </span>Patients treated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> frequently become excessively anticoagulated, even those who have been stable for many months. The most common causes of a supratherapeutic INR are interactions between warfarin and other drugs, diet, or superimposed conditions (eg, liver disease, malabsorption) that may interfere with warfarin ingestion, absorption, or metabolism. Many of these risk factors are modifiable and/or could be accompanied by more intensive monitoring.</p><p>Major classes of modifiable factors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient comorbidities (eg, heart failure)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute illnesses (eg, infections, gastrointestinal illnesses)</p><p class="bulletIndent1"><span class="glyph">●</span>Medication interactions (eg, antimicrobials [antibiotics, antifungals], <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> [if taken at larger-than-recommended daily doses], nonsteroidal antiinflammatory drugs [NSAIDs]) (see <a class="local">'Drug interactions'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Large day-to-day variations in vitamin K intake</p><p class="bulletIndent1"><span class="glyph">●</span>Errors in dosing (eg, patient taking wrong dose or wrong tablet strength, or taking extra doses inadvertently)</p><p></p><p>Comorbidities should be managed appropriately, and acute illnesses should be addressed promptly. Patients should be advised to discuss any new medication or supplement with their clinician, and clinicians are advised to evaluate potentially important interactions when introducing a new medication. If interacting drugs must be used, INR monitoring frequency should be increased.</p><p>Evidence for the contribution of various medical conditions to supratherapeutic INR values was reviewed in a prospective cohort study with a nested case-control design from among 17,056 outpatients treated with vitamin K antagonists in a regional Red Cross anticoagulation clinic over a two-year period [<a href="#rid25">25</a>]. Multivariate analysis identified the following comorbidities associated with an INR ≥6:</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea – Odds ratio (OR) 12.8</p><p class="bulletIndent1"><span class="glyph">●</span>Fever – OR 2.9</p><p class="bulletIndent1"><span class="glyph">●</span>Relapsed (incident) congestive heart failure – OR 3.0</p><p class="bulletIndent1"><span class="glyph">●</span>Stable (prevalent) impaired liver function – OR 2.8</p><p class="bulletIndent1"><span class="glyph">●</span>Stable (prevalent) congestive heart failure – OR 1.6</p><p></p><p>Companion analyses from the same cohort evaluated the effects of potentially interacting medications and dietary and lifestyle factors [<a href="#rid26">26,27</a>]. Importantly, while it is useful to pay close attention to dietary intake of vitamin K  (<a class="graphic graphic_table graphicRef78708" href="/d/graphic/78708.html" rel="external">table 3</a>), the goal is to maintain a moderate constant level of intake rather than to eliminate vitamin K from the diet.</p><p>In addition to these modifiable risk factors, fixed patient characteristics including female sex, increased age, and previous INR instability or hemorrhage have been associated with a greater sensitivity to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and/or an increased risk of bleeding [<a href="#rid2">2,28-31</a>]. Factors that increase bleeding risk independent of effects on INR should also be minimized when possible. (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H1766244"><span class="h1">DIETARY FACTORS</span></p><p class="headingAnchor" id="H955069"><span class="h2">Vitamin K intake</span><span class="headingEndMark"> — </span>Individuals anticoagulated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> generally are sensitive to fluctuations in vitamin K intake, and adequate INR control requires close attention to the amount of vitamin K ingested from dietary and other sources [<a href="#rid32">32</a>]. Vitamin K bypasses the target enzyme of the vitamin K antagonists (VKAs), the vitamin K epoxide reductase; thus, large variations in dietary vitamin K may result in INR instability. (See <a class="local">'Mechanism of action'</a> above.)</p><p>The goal of monitoring vitamin K intake is to maintain a moderate, constant level of intake rather than to eliminate vitamin K from the diet. Specific guidance from anticoagulation clinics may vary, but a general principle is that maintaining a consistent level of vitamin K intake should not interfere with a nutritious diet.</p><p>Patients taking <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may wish to be familiar with possible sources of vitamin K (to avoid inconsistency). For example, one-half cup of spinach contains &gt;500 mcg of vitamin K. Other vegetables high in vitamin K include other greens (eg, beet, collard, mustard, turnip, kale) and Brussels sprouts  (<a class="graphic graphic_table graphicRef78708" href="/d/graphic/78708.html" rel="external">table 3</a>). In contrast, most lettuces and other green vegetables have moderate or low vitamin K content (eg, &lt;100 mcg per one-cup serving).</p><p>Additional sources of significant amounts of vitamin K include multivitamins, calcium supplements, nutritional and vitamin-fortified drinks, and some herbal products [<a href="#rid33">33-35</a>]. Individuals receiving a VKA must closely check the ingredients of any over-the-counter supplement and avoid inadvertent ingestion of high vitamin K doses from these products.</p><p>Several small studies have demonstrated the relationship between vitamin K intake and INR control. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort of 147 adults receiving long-term VKA therapy, those with good INR control, defined as time in the therapeutic range of ≥66 percent, had more regular, less variable day-to-day vitamin K intake (median range, 1.76 versus 2.73 mcg/kg/day) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort of 1157 individuals chosen for stable anticoagulation control at baseline (defined as four consecutive INR readings in the therapeutic range), 335 (29 percent) subsequently had a subtherapeutic INR [<a href="#rid37">37</a>]. Daily vitamin K intake in 63 of these individuals was assessed by a food frequency questionnaire and categorized as low, normal, or high (&lt;100 mcg, 100 to 300 mcg, or &gt;300 mcg, respectively). There was a trend towards an inverse relationship between good INR control and daily vitamin K intake, with a slightly greater likelihood of therapeutic INR in those with high vitamin K intake and a slightly lower likelihood of therapeutic INR in those with low intake, although neither reached statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review that evaluated dietary vitamin K intake in 26 individuals who had stable INR control, defined as no change in <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose over six months and standard deviation of INR &lt;0.5, compared with 26 individuals who had unstable control, there was a correlation between stable control and a higher mean daily vitamin K intake (76 versus 29 mcg) [<a href="#rid38">38</a>]. Dietary fat intake was also evaluated because vitamin K is fat soluble, and this did not correlate with INR control.</p><p></p><p>Administration of low daily doses of vitamin K (eg, 100 to 200 mcg daily) may be tried in selected patients with unexplained INR variation, although high-quality evidence to suggest this will be effective for all (or most) patients is lacking. This practice and evidence to support it are discussed separately. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Poor INR control/vitamin K supplementation'</a>.)</p><p>Intestinal microflora produce vitamin K2, and one of the ways antibiotics contribute to variability in the prothrombin time (PT)/INR is by reducing intestinal vitamin K synthesis [<a href="#rid39">39</a>]. (See <a class="local">'Antibacterial and antifungal drugs'</a> below.)</p><p class="headingAnchor" id="H1766251"><span class="h2">Other dietary factors</span><span class="headingEndMark"> — </span>In general, patients are advised to consume a healthy diet, and they should not avoid fruits and vegetables for fear of altering the INR, with the exception of regulating vitamin K intake as discussed in the preceding section. (See  <a class="medical medical_review" href="/d/html/5364.html" rel="external">"Healthy diet in adults"</a>.)</p><p>Cranberry juice and grapefruit juice have very low vitamin K content but have been reported to affect VKA anticoagulation in some studies, and some anticoagulation clinics advise patients to limit their intake to one or two servings (or less) per day [<a href="#rid40">40-45</a>].</p><p>Caffeine-containing beverages generally are not observed to have major effects on INR control, although cases of individuals consuming large quantities of coffee products (eg, liters per day) associated with inappropriately low INR have been reported [<a href="#rid46">46</a>]. </p><p>Alcohol in low or moderate amounts (eg, one or two servings per day) is unlikely to have major effects on the INR, and regular use is less likely to alter metabolism than erratic use (eg, binge drinking). Contributions of excess alcohol intake are presented below. (See <a class="local">'Tobacco, marijuana, and alcohol'</a> below.)</p><p>Weight-loss diets may lead to alterations in <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose requirements due to changes in vitamin K intake or warfarin metabolism; individuals on weight-loss diets generally should have more frequent testing of the INR.</p><p class="headingAnchor" id="H1766258"><span class="h2">Overall nutritional status</span><span class="headingEndMark"> — </span>Individuals who are severely malnourished may be more sensitive to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. Severe vitamin K deficiency may occur, but this is uncommon in the absence of a broad-spectrum antibiotic, especially in outpatients.</p><p class="headingAnchor" id="H3800086"><span class="h1">MEDICATION ADHERENCE</span><span class="headingEndMark"> — </span>Medication adherence for vitamin K antagonists (VKAs) can be challenging due to the need for frequent monitoring and dose adjustments, dietary restrictions, medication interactions, and, in some cases, use of different medication doses on different days to achieve the optimal weekly intake.</p><p>Interventions to improve medication adherence include patient education and counseling and availability of a clinician to answer questions regarding dose adjustments and medication interactions. These are facilitated by the use of an anticoagulation clinic. Additional patients are able to improve adherence using INR self-monitoring and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> self-management approaches that incorporate pill boxes, dosing calendars, smartphone applications, and dosing algorithms. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Outpatient management'</a>.)</p><p>Reducing the number of medications prescribed may be helpful, if this can be done safely. In a review of anticoagulation control in a cohort of over 100,000 patients, receipt of 16 or more medications resulted in a 5 percent reduction in INR control compared with seven or fewer medications [<a href="#rid47">47</a>].</p><p>For individuals with decreased medication adherence, it is important to determine the reasons and contributing factors. Some factors such as difficulty maintaining stable daily dietary vitamin K intake may be improved with use of a direct-acting oral anticoagulant (DOAC) in the appropriate clinical setting. However, other factors such as inability to take the medication at the correct daily dose and frequency may not be improved with the use of a DOAC, especially since the ability to monitor adherence with a DOAC is not readily available.</p><p>Impaired cognition, depressed mood, and inadequate health literacy also have been implicated in <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> instability, especially in older patients [<a href="#rid48">48</a>]. Warfarin overdose, either intentional (eg, suicide attempt) or unintentional (eg, toddler) has been reported, with a mean peak INR of approximately 6 [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H447124"><span class="h1">DRUG INTERACTIONS</span></p><p class="headingAnchor" id="H3799397"><span class="h2">Summary of drug interactions</span><span class="headingEndMark"> — </span>A large number of drugs interact with vitamin K antagonists (VKAs) by a variety of mechanisms, and additional interacting drugs continue to be introduced  (<a class="graphic graphic_table graphicRef62697" href="/d/graphic/62697.html" rel="external">table 4</a>) [<a href="#rid50">50</a>]. Determining clinically important drug interactions that prolong the prothrombin time (PT) and international normalized ratio (INR) is challenging. With some drugs, the evidence substantiating claims is very limited; in other cases, the evidence is strong but the magnitude of effect is small [<a href="#rid12">12</a>]. </p><p>Patients should be advised to discuss any new medication or over-the-counter supplement with the clinician managing their anticoagulation, and clinicians are advised to confirm whether a clinically important drug-drug interaction has been reported when introducing a new medication in a patient anticoagulated with a VKA. Resources for this are available in the <a class="external" href="/drug-interactions">drug interactions program</a> and through various other websites.</p><p>Medications interact with VKAs by the following mechanisms [<a href="#rid39">39,51-53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged PT/INR:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Altered intestinal flora, with reduced intestinal vitamin K synthesis</strong> – Antimicrobials, especially cotrimoxazole, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, macrolides, and fluoroquinolones</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inhibition of hepatic CYP2C9, with reduced </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a><strong> metabolism</strong> – Many agents (eg, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, and sulfamethoxazole)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Interruption of vitamin K recycling</strong> – <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Displacement of </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a><strong> from albumin</strong> – Any medication that binds albumin; however, this effect is usually minor</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased bleeding risk independent of PT/INR:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Injury to gastrointestinal mucosa</strong> – <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> and nonsteroidal antiinflammatory drugs (NSAIDs)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Interference with platelet function</strong> – Anti-platelet drugs, including <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, NSAIDs, <a class="drug drug_general" data-topicid="9377" href="/d/drug information/9377.html" rel="external">dipyridamole</a>, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>, and <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other (incompletely characterized</strong>) – Gingko biloba, dong quai, fenugreek, chamomile</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced anticoagulation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction hepatic CYP2C9, with increased </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a><strong> metabolism</strong> – <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bypass </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a><strong> effect via large amounts of vitamin K</strong> – Some vitamin and calcium supplements</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incompletely characterized</strong> – St. John's wort</p><p></p><p>The tables list common VKA interacting medications  (<a class="graphic graphic_table graphicRef62697" href="/d/graphic/62697.html" rel="external">table 4</a>) and herbal products  (<a class="graphic graphic_table graphicRef76808" href="/d/graphic/76808.html" rel="external">table 5</a>), and details of some common interactions are discussed in more detail in the following sections.</p><p>Information regarding the COVID-19 therapy <a class="drug drug_general" data-topicid="134695" href="/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> (Paxlovid) is limited. One small study suggested an initial decrease in INR in approximately one-half of treated patients, although changes in <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dosing were not required [<a href="#rid54">54</a>].</p><p>Medication interactions should be minimized when possible. Individuals with high fever or severe intercurrent illness are likely to require additional evaluation and monitoring for the potential effect of the illness itself on their anticoagulant (see <a class="local">'Intercurrent illness'</a> below). If an interacting medication is introduced, the PT/INR should be monitored more frequently to allow VKA dose adjustments as needed. (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Other medications'</a>.)</p><p>There is evidence to suggest that individuals with a personal history of venous thromboembolism (VTE) can use estrogen in combination with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and expect a reasonably low risk of VTE recurrence. A study of 1888 females who were receiving an anticoagulant after an initial VTE episode did not find an association between recurrent VTE risk and the use of hormonal therapy [<a href="#rid55">55</a>]. A levonorgestrel-releasing intrauterine device is thought to be relatively safe. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection", section on 'Special populations'</a> and  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a> and  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p class="headingAnchor" id="H3799403"><span class="h2">Common drug interaction examples</span></p><p class="headingAnchor" id="H1161414"><span class="h3">Aspirin/NSAIDs</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, nonsteroidal antiinflammatory drugs (NSAIDs), or other antiplatelet agents such as <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9377" href="/d/drug information/9377.html" rel="external">dipyridamole</a> increases the risk of bleeding in patients treated with VKAs [<a href="#rid51">51,56-60</a>]. Thus, for patients for whom other interventions are available, these medications are avoided for routine management of minor pain or fever. Patients anticoagulated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> generally are advised not to use aspirin for primary prevention of cardiovascular disease. In patients who have a history of acute coronary syndrome (but also require warfarin for other reasons), the risks and benefits of adding aspirin or other antiplatelet medications must be individualized. (See  <a class="medical medical_review" href="/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p><p>For those who do require an NSAID, use of a COX-2 selective agent may lead to fewer bleeding complications as these agents do not interfere with platelet function. (See  <a class="medical medical_review" href="/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs", section on 'Lack of platelet inhibition and use during anticoagulation'</a>.)</p><p>The lower bleeding risk with COX-2 selective NSAIDs was demonstrated in a nested case-control study of patients in the Netherlands taking phenprocoumon or <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a> along with NSAIDs. Over a two-year period there were 1491 bleeding episodes, 15 percent of which involved the use of NSAIDs [<a href="#rid57">57</a>]. On multiple regression analysis, there was a significantly increased risk for bleeding in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of a nonselective versus a COX-2 selective NSAID – odds ratio (OR) 3.1</p><p class="bulletIndent1"><span class="glyph">●</span>NSAID use for &gt;1 month (versus ≤1 month) – OR 3.0</p><p class="bulletIndent1"><span class="glyph">●</span>Last INR &gt;4.0 (versus ≤4.0) – OR 1.9</p><p></p><p>There are multiple potential mechanisms by which antiplatelet agents can increase bleeding risk, including gastrointestinal toxicity, interference with normal platelet function, and increases in INR [<a href="#rid56">56-59</a>]. This subject is discussed separately. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action"</a>.)</p><p class="headingAnchor" id="H1764829"><span class="h3">Acetaminophen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> can theoretically interfere with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation, especially at higher doses (eg, &gt;2 to 3 grams daily for more than two to three days). Greater doses or durations have been demonstrated to increase the PT/INR in some patients. We instruct patients that if they will use ≥2 g/day of acetaminophen for at least three consecutive days, their INR should be tested three to five days after the first acetaminophen dose [<a href="#rid53">53</a>]. However, it is important to note that acetaminophen taken at recommended doses is generally much safer for pain than nonsteroidal antiinflammatory drugs (NSAIDs) in individuals receiving warfarin.</p><p>The mechanism(s) by which <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> prolongs the PT/INR are incompletely understood and are thought to involve changes in <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> potency rather than warfarin metabolism (eg, pharmacodynamic rather than pharmacokinetic effects) [<a href="#rid53">53,61</a>]. The main role appears to be interruption of vitamin K recycling between reduced and oxidized forms (see <a class="local">'Mechanism of action'</a> above) by acetaminophen metabolites or oxidative stress [<a href="#rid53">53,62</a>].</p><p>Evidence for prolongation of the PT/INR by <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> comes from observational data and small randomized trials [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Several small randomized trials, each involving fewer than 50 patients, have compared the effect of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> (2 to 4 grams per day) with placebo [<a href="#rid63">63-66</a>]. These have found increases in the INR associated with acetaminophen use (mean increase, approximately 1.0; mean maximum INR, approximately 3.5).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study that compared 93 outpatients receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> who had INR &gt;6.0 with 196 controls receiving warfarin with a therapeutic INR, those with an INR &gt;6.0 were more likely to have received <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> [<a href="#rid67">67</a>]. The highest dose category (≥9100 mg of acetaminophen per week, equivalent to four 325 mg tablets per day) was associated with a 10-fold increase in the likelihood of INR &gt;6.0 (16 versus 3 percent; adjusted odds ratio [OR] 10.0 [95% CI 2.6-37.9]). Lower weekly doses had smaller effects, and weekly doses &lt;2.2 grams did not increase the odds of an INR &gt;6.0.</p><p></p><p class="headingAnchor" id="H447389"><span class="h3">Antibacterial and antifungal drugs</span><span class="headingEndMark"> — </span>A variety of antibiotics affect <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> metabolism, especially <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> and macrolides (eg, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>), as well as antifungal agents (<a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>)  (<a class="graphic graphic_table graphicRef62697" href="/d/graphic/62697.html" rel="external">table 4</a>) [<a href="#rid50">50,68</a>]. Even topical agents (eg, topical <a class="drug drug_general" data-topicid="9400" href="/d/drug information/9400.html" rel="external">econazole</a> or bifonazole) have been reported to alter metabolism [<a href="#rid69">69</a>]. Most agents lead to PT/INR prolongation; however, some (eg, <a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">dicloxacillin</a>, <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>) decrease warfarin effect [<a href="#rid70">70</a>]. It may be prudent to substitute alternative antibiotics when available and equally efficacious; when one of these antibiotics must be administered, more intensive warfarin monitoring generally is needed.</p><p>The mechanisms by which these agents alter anticoagulation include disruption of intestinal microflora, inhibition (or less commonly, induction) of hepatic CYP2C9 or other cytochrome P-450 isoforms, and other changes (eg, changes in diet). Importantly, the underlying infection may also affect anticoagulation status through effects on metabolism, reduced oral intake, diarrhea, or other mechanisms. (See <a class="local">'Intercurrent illness'</a> below.)</p><p>Evidence for the role of various agents comes from a variety of observational studies. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study evaluated the effect of antibiotic use in 5857 individuals receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and an antibiotic for an upper respiratory infection who had an INR 5.0 versus 570 controls who had an upper respiratory infection but did not receive an antibiotic and 5579 controls who did not have an upper respiratory infection (all assessments were based on prescriptions filled during the study period) [<a href="#rid68">68</a>]. The percentage of patients with an INR &gt;5.0 was highest in the patients receiving an antibiotic (3.2 versus 2.6 percent in controls with an upper respiratory infection and 2.2 percent in controls without an infection). Antimicrobials most frequently implicated in a supratherapeutic INR included <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>. Clinically relevant bleeding and thromboembolism were infrequent and similar across all groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based study evaluated the relationship between INR and antibiotic use in 1124 patients receiving <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a> or phenprocoumon [<a href="#rid28">28</a>]. Of these, 351 (31 percent) had an INR &gt;6.0. The risks of over-anticoagulation was greatest with <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (adjusted relative risk [RR] 20.1; 95% CI 10.7-37.9), <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> (RR 79), <a class="drug drug_general" data-topicid="9710" href="/d/drug information/9710.html" rel="external">norfloxacin</a> (RR 45), <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (RR 32), <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (RR 32), and <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> (RR 18). The increases in INR above the therapeutic range often occurred within the first three days of antibiotic usage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A case-control study evaluated the relationship between upper gastrointestinal (GI) bleeding and antibiotics commonly used to treat urinary tract infections in patients receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid71">71</a>]. Of 134,637 patients in a database, there were 2151 cases of upper GI bleeding (1.6 percent). Compared with controls, those with upper GI bleeding were more likely to have received cotrimoxazole (adjusted OR 2.84; 95% CI 2.33-6.33) or <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (adjusted OR 1.94; 95% CI 1.28-2.95). In contrast, there was no significant association with use of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9704" href="/d/drug information/9704.html" rel="external">nitrofurantoin</a>, or <a class="drug drug_general" data-topicid="9710" href="/d/drug information/9710.html" rel="external">norfloxacin</a>.</p><p></p><p class="headingAnchor" id="H447437"><span class="h3">Anti-ulcer medications</span><span class="headingEndMark"> — </span>Anti-ulcer medications, including H2-receptor blockers, proton pump inhibitors (PPIs), and <a class="drug drug_general" data-topicid="9953" href="/d/drug information/9953.html" rel="external">sucralfate</a> may potentially affect <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation, although this is not a major cause of INR variability in our practice. We generally do not discourage patients from using these drugs, especially if they are at high risk of gastrointestinal bleeding. </p><p>A discussion about use of these medications to reduce bleeding risk is presented separately. (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Gastric protection'</a>.)</p><p><a class="drug drug_general" data-topicid="9953" href="/d/drug information/9953.html" rel="external">Sucralfate</a> may decrease absorption of vitamin K antagonists. If it must be given, the vitamin K antagonist should be given at least two hours before or at least six hours after sucralfate.</p><p class="headingAnchor" id="H1766475"><span class="h1">TOBACCO, MARIJUANA, AND ALCOHOL</span><span class="headingEndMark"> — </span>Tobacco and excess alcohol use have well described adverse health effects, some of which are associated with increased thromboembolic risk that may have prompted the vitamin K antagonist (VKA) administration in the first place. (See  <a class="medical medical_review" href="/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a> and  <a class="medical medical_review" href="/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment", section on 'Adverse consequences'</a>.)</p><p>In addition, tobacco, marijuana, and excess alcohol may alter the anticoagulant effect of VKAs, as illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smokeless tobacco</strong> – Smokeless tobacco use is especially prevalent in India and Southeast Asia [<a href="#rid72">72</a>]. There are limited data on the effects on anticoagulation, but a case report has raised the concern that smokeless tobacco has a high vitamin K content, which could dramatically affect <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation [<a href="#rid73">73</a>]. This effect is likely to be more significant than the induction of hepatic cytochromes that is seen with smoking tobacco.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tobacco</strong> – The effect of chronic cigarette smoking on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> metabolism was evaluated in a systematic review and that included 13 studies (prospective and retrospective series) involving over 3000 patients [<a href="#rid74">74</a>]. A meta-analysis of the studies that evaluated warfarin dose requirement found that smoking increased the dose requirement by 12 percent, corresponding to a requirement of 2.26 additional mg of warfarin per week. However, two studies that evaluated the effect of chronic smoking on INR control found equivalent control in smokers and non-smokers.</p><p></p><p class="bulletIndent2">The mechanisms by which cigarette smoking interacts with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> metabolism is by causing enhanced drug clearance through induction of hepatic cytochrome P-450 activity (eg, CYP1A1, CYP1A2, CYP2E1) by polycyclic aromatic hydrocarbons in cigarette smoke [<a href="#rid74">74</a>]. Nicotine itself (eg, in nicotine replacement products, electronic cigarettes) is not thought to alter warfarin metabolism [<a href="#rid75">75,76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Marijuana</strong> – Components of marijuana are potent inhibitors of CYP2C9 activity. Case reports and systematic reviews suggest that marijuana smoking or consumption of other products (cannabidiol [CBD] oil, tetrahydrocannabinol [THC], <a class="drug drug_general" data-topicid="134930" href="/d/drug information/134930.html" rel="external">medical cannabis</a> or cannabinoids) can increase the INR [<a href="#rid77">77-82</a>]. Individuals taking a VKA should be counseled about these effects, and the possibility of interference may be discussed in individuals with high INRs or INR variability. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> dose adjustments may be required in some cases. (See  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Cannabis and cannabinoids'</a>.)</p><p></p><p class="bulletIndent2">Cases in which marijuana has been mixed with a superwarfarin compound (brodifacoum) have also been reported [<a href="#rid83">83</a>]. This subject is discussed separately. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Superwarfarin poisoning'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excess alcohol</strong> – The interaction between excess alcohol use and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation was evaluated in a case-control study that compared alcohol use in 265 individuals receiving warfarin who had major bleeding with 305 controls from the same cohort receiving warfarin who did not have major bleeding [<a href="#rid84">84</a>]. The risk of major bleeding was increased with moderate to severe alcohol use and with heavy episodic drinking (odds ratio [OR] 2.10; 95% CI 1.08-4.07 and OR 2.36; 95% CI 1.24-4.50, respectively).</p><p></p><p class="bulletIndent1">Mechanisms by which alcohol use interacts with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation are many, and the contribution of various factors depends greatly on the amount of intake and the severity of associated liver disease. Excess alcohol consumption may interfere with warfarin metabolism. Severe liver disease may also be associated with coagulopathy, thrombocytopenia, and/or gastrointestinal varices, all of which increase bleeding risk independent of effects on warfarin metabolism. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p>We counsel patients to discontinue smoking and chewing tobacco for health reasons and to avoid excess or erratic alcohol use. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Counseling and patient education'</a>.)</p><p>Individuals who alter their tobacco use should inform their anticoagulation provider so that potential changes in the INR may be anticipated and appropriate testing and dose changes instituted. Those participating in a smoking cessation program may benefit from more frequent INR monitoring because they may require <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> dose reduction. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Monitoring interval'</a>.)</p><p class="headingAnchor" id="H1162421"><span class="h1">COMORBIDITIES</span><span class="headingEndMark"> — </span>The major comorbidities that affect anticoagulation control are liver disease, kidney dysfunction, and heart failure. In addition, other comorbidities such as metastatic cancer, diabetes, or uncontrolled hyperthyroidism may also play a role [<a href="#rid2">2</a>]. None of these comorbidities is a contraindication to vitamin K antagonist (VKA) use; in fact, many increase thromboembolic risk. In our experience, patients with severe chronic kidney or liver disease are at increased risk for erratic INR results as well as for hemorrhagic complications. Closer attention to monitoring and dose adjustments is often indicated in these settings and, in some cases, the risks of anticoagulant therapy may outweigh the potential benefit.</p><p class="headingAnchor" id="H3800042"><span class="h2">Liver, kidney, heart, and thyroid disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver</strong> – The liver is the predominant site of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> metabolism. It is also the source of the majority of coagulation factors. Thus, liver disease can affect warfarin dosage, INR control, and coagulation in general. Importantly, individuals with severe liver disease are not "auto-anticoagulated," because they often have a combination of abnormalities that both impair hemostasis and increase thrombotic risk. For patients with significant liver disease who need anticoagulation, low molecular weight heparin is often a more practical alternative than warfarin. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a> and  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> undergoes partial excretion in the kidney. Patients with kidney disease can receive warfarin, and management is generally similar to the population without impaired kidney function; however, dose requirement may be lower. This was illustrated in a cohort of 980 participants in a pair of prospective cohort studies that analyzed the effect of a variety of factors on warfarin dosing [<a href="#rid85">85</a>]. Decreasing kidney function correlated with a lower warfarin dose requirement, with dose reductions of approximately 10 and 20 percent in those with moderate and severely impaired kidney function. Severely impaired kidney function is an independent risk factor for adverse outcomes (both bleeding and thrombosis) in patients who take warfarin; the net benefit of vitamin K antagonists in patients with advanced kidney disease is being increasingly scrutinized. A 2015 meta-analysis of warfarin use in dialysis-dependent individuals with atrial fibrillation found no reduction of mortality with warfarin use (hazard ratio [HR] 1.03; 95% CI 0.96-1.11) [<a href="#rid86">86</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart</strong> – Heart failure has been shown to interfere with INR stabilization. As an example, in a database of 15,276 individuals with atrial fibrillation, INR stabilization could not be achieved in 3809 (25 percent) [<a href="#rid87">87</a>]. Heart failure was associated with a lower likelihood of INR stabilization (odds ratio [OR] 0.78; 95% CI 0.70-0.87). In a case-control study that included 533 individuals with stable INR control and 2555 comparator patients, INR control was better in individuals without heart failure (OR 2.08; 95% CI 1.36-3.17) [<a href="#rid29">29</a>]. Other studies have observed similar correlations between heart failure and reduced INR control [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">Discussions of antithrombotic therapy in patients with heart failure or atrial fibrillation, including indications, choice of agent(s), risks, benefits, and other management details, are presented separately. (See  <a class="medical medical_review" href="/d/html/3502.html" rel="external">"Antithrombotic therapy in patients with heart failure"</a> and  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid</strong> – Thyroid disease has been reported to affect INR control, especially amiodarone-induced thyrotoxicosis, which can occur with 10 to 15 percent of individuals taking <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> [<a href="#rid89">89</a>]. This effect is independent from the known effect of amiodarone on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> metabolism, which also may increase the INR  (<a class="graphic graphic_table graphicRef62697" href="/d/graphic/62697.html" rel="external">table 4</a>). </p><p></p><p class="bulletIndent1">Hyperthyroidism unrelated to <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> can also potentiate the effect of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, leading to increased bleeding risk and increased INR; conversely, hypothyroidism can blunt the warfarin response and decrease the INR [<a href="#rid89">89</a>]. The purported mechanisms involve clearing of clotting factors (more rapid clearance in hyperthyroidism potentiating warfarin effect; reduced clearance in hypothyroidism diminishing warfarin effect).</p><p></p><p>These associations may warrant closer monitoring in individuals receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, especially during initiation of warfarin or treatment of the underlying comorbidity. </p><p class="headingAnchor" id="H1764900"><span class="h2">Intercurrent illness</span><span class="headingEndMark"> — </span>Acute illnesses may alter anticoagulation through effects on vitamin K intake, VKA metabolism, and medication interactions, especially infections and gastrointestinal illnesses [<a href="#rid68">68</a>]. We generally monitor the INR more frequently in any patient with an infection requiring antibiotic therapy, with the monitoring interval individualized according to the type and severity of illness, oral intake, need for added medications, and any other relevant factors. Patients hospitalized for an acute illness generally have monitoring of the prothrombin time (PT)/INR on a daily or every-other-day basis.</p><p>The impact of an acute illness on INR control was demonstrated in a case-control study that compared 93 outpatients receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> who had INR &gt;6.0 with 196 controls receiving warfarin who did not have an INR &gt;6.0 [<a href="#rid67">67</a>]. Those with an INR &gt;6.0 were more likely to have had a recent diarrheal illness (odds ratio [OR] 3.5; 95% CI 1.4-8.6) or to have decreased oral intake (OR 2.6; 95% CI 2.2-30).</p><p>The effect of hospitalization on INR control was illustrated in a retrospective cohort study using a laboratory database that included 5380 patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. During a one-year period, 951 (17 percent) were hospitalized [<a href="#rid90">90</a>]. All measures of anticoagulation control changed in the peri-hospitalization period, with an INR above the therapeutic range more likely before hospitalization and an INR below the therapeutic range more likely after discharge.</p><p class="headingAnchor" id="H2453997"><span class="h1">GENETIC FACTORS</span><span class="headingEndMark"> — </span>Genetic polymorphisms have been implicated in altered sensitivity to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and other vitamin K antagonists (VKAs); however, we do not advocate routine genetic testing prior to VKA administration as randomized trials have shown that this practice does not affect patient-important outcomes. Results of these trials are presented separately. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Baseline testing'</a>.)</p><p>The major genes involved in VKA sensitivity are vitamin K epoxide reductase, subunit 1 (<em>VKORC1</em>), the drug target; and hepatic cytochrome P450 2C9 isoform (<em>CYP2C9</em>), which metabolizes the drug to an inactive form [<a href="#rid91">91-97</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>VKORC1</em></strong> – The vitamin K epoxide reductase complex recycles vitamin K to produce the reduced form that serves as a cofactor in gamma carboxylation of vitamin K-dependent coagulation factors. <em>VKORC1</em> encodes a subunit of this complex. A number of polymorphisms in <em>VKORC1</em> have been demonstrated to affect dose requirements of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and other VKAs [<a href="#rid92">92,98-103</a>]. (See <a class="local">'Mechanism of action'</a> above and  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>CYP2C9</em></strong> – Cytochrome P450 2C9 is the primary hepatic enzyme responsible for metabolic clearance of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a> [<a href="#rid98">98,104-110</a>]. Genetic variation in the <em>CYP2C9</em> gene has been demonstrated to affect warfarin and acenocoumarol dose requirements, although to a lesser degree than <em>VKORC1</em> variants in some studies [<a href="#rid94">94,98,108-116</a>]. Anticoagulation with phenprocoumon, which has a longer half-life, may be less affected by <em>CYP2C9</em> polymorphisms than warfarin or acenocoumarol [<a href="#rid13">13</a>]. (See <a class="local">'VKA metabolism'</a> above and  <a class="medical medical_review" href="/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'CYP isoenzymes and drug metabolism'</a>.)</p><p></p><p>Case reports have identified mutations in other genes (eg, <em>CYP4F2</em>, the gene encoding the cytochrome P450 4F2 isoform; and folylpolyglutamate synthase [<em>FPGS</em>], which encodes an enzyme involved in folate metabolism) that lead to more dramatic effects on VKA dose requirements; these are extremely rare [<a href="#rid117">117-119</a>]. </p><p class="headingAnchor" id="H1916899602"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86639.html" rel="external">"Patient education: Prothrombin time and INR (PT/INR) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biology</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> and related vitamin K antagonists ([VKAs], <a class="drug drug_general" data-topicid="9159" href="/d/drug information/9159.html" rel="external">acenocoumarol</a>, phenprocoumon, fluindione) block vitamin K epoxide reductase in the liver, leading to reduced gamma carboxylation of vitamin K-dependent factors (II [prothrombin], VII, IX, and X). Full anticoagulation requires depletion of factor X and factor II activities to approximately 20 percent. This may take up to three days, and initial prolongation of the prothrombin time (PT) and international normalized ratio (INR) does not reflect full anticoagulation. This is the basis for overlapping ("bridging") with another anticoagulant (generally unfractionated or low molecular weight [LMW] heparin) in individuals at high thromboembolic risk. VKAs are primarily metabolized in the liver by hepatic P-450 2C9. Half-lives of VKAs differ substantially. (See <a class="local">'Biology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diet</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> anticoagulation is sensitive to fluctuations in vitamin K intake, and INR control requires close attention to vitamin K in the diet and supplements  (<a class="graphic graphic_table graphicRef78708" href="/d/graphic/78708.html" rel="external">table 3</a>). The goal is to maintain a moderate, constant level of intake rather than to eliminate vitamin K. (See <a class="local">'Dietary factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adherence</strong> – Medication adherence for VKAs can be challenging, and interventions to improve adherence (eg, patient education, availability of a clinician to answer questions regarding dose adjustments and medication interactions) are facilitated by the use of an anticoagulation clinic and/or self-management approaches. (See <a class="local">'Medication adherence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Many drugs  (<a class="graphic graphic_table graphicRef62697" href="/d/graphic/62697.html" rel="external">table 4</a>), over-the-counter medications, and herbal remedies  (<a class="graphic graphic_table graphicRef76808" href="/d/graphic/76808.html" rel="external">table 5</a>) interact with VKAs. Most increase bleeding risk. Patients should be advised to discuss any new medication or supplement with their clinician, and clinicians are advised to evaluate potentially important interactions when introducing a new medication. Interactions are avoided or minimized when possible; if interacting drugs must be used, monitoring frequency should be increased. (See <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking and alcohol</strong> – Smoking and alcohol may alter the effect of VKAs. We counsel patients to discontinue smoking for health reasons and to avoid excess or erratic alcohol use. Individuals participating in smoking cessation programs may benefit from more frequent INR monitoring. (See <a class="local">'Tobacco, marijuana, and alcohol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbidities</strong> – Chronic kidney or liver dysfunction, heart failure, and thyroid disease may impact INR control and VKA dose requirements. Acute illnesses, especially infections, gastrointestinal illnesses, and illnesses requiring hospitalization, may alter time in the therapeutic range and warrant closer attention to monitoring and dose adjustments. (See <a class="local">'Comorbidities'</a> above and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Monitoring interval'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic variation</strong> – Genetic polymorphisms have been implicated in altered sensitivity to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and other VKAs, including polymorphisms in genes such as <em>VKORC1</em>, which encodes a subunit of the vitamin K epoxide reductase complex, and <em>CYP2C9</em>, which encodes a hepatic cytochrome. However, genetic testing has been shown not to improve INR control, and we do not advocate routine genetic testing prior to VKA administration. (See <a class="local">'Genetic factors'</a> above.)</p><p></p><p class="headingAnchor" id="H453730023"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate acknowledges Karen A Valentine, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.</a></li><li><a class="nounderline abstract_t">Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:204S.</a></li><li><a class="nounderline abstract_t">Lind SE, Callas PW, Golden EA, et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8:48.</a></li><li><a class="nounderline abstract_t">Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993; 92:2131.</a></li><li><a class="nounderline abstract_t">O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation 1968; 38:169.</a></li><li><a class="nounderline abstract_t">Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314:1298.</a></li><li class="breakAll">http://www.who.int/bloodproducts/ivd/thromboplastin_reagents/en/ (Accessed on May 01, 2015).</li><li><a class="nounderline abstract_t">Smith SA, Morrissey JH. Properties of recombinant human thromboplastin that determine the International Sensitivity Index (ISI). J Thromb Haemost 2004; 2:1610.</a></li><li><a class="nounderline abstract_t">Brandjes DP, Heijboer H, Büller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327:1485.</a></li><li><a class="nounderline abstract_t">Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008; 25:61.</a></li><li><a class="nounderline abstract_t">Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther 2008; 6:57.</a></li><li><a class="nounderline abstract_t">Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095.</a></li><li><a class="nounderline abstract_t">Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100:1052.</a></li><li><a class="nounderline abstract_t">Ellis DJ, Usman MH, Milner PG, et al. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 2009; 120:1029.</a></li><li><a class="nounderline abstract_t">Whitlock RP, Fordyce CB, Midei MG, et al. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. Thromb Haemost 2016; 116:241.</a></li><li><a class="nounderline abstract_t">Fihn SD, Gadisseur AA, Pasterkamp E, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90:260.</a></li><li><a class="nounderline abstract_t">Mentré F, Pousset F, Comets E, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther 1998; 63:64.</a></li><li><a class="nounderline abstract_t">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.</a></li><li class="breakAll">http://packageinserts.bms.com/pi/pi_coumadin.pdf (Accessed on June 02, 2015).</li><li><a class="nounderline abstract_t">Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109:2419.</a></li><li><a class="nounderline abstract_t">Lefrère JJ, Guyon F, Horellou MH, et al. [Resistance to vitamin K antagonists. 6 cases]. Ann Med Interne (Paris) 1986; 137:384.</a></li><li><a class="nounderline abstract_t">Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol 1993; 35:327.</a></li><li><a class="nounderline abstract_t">Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 1996; 16:1009.</a></li><li><a class="nounderline abstract_t">Pérez-Andreu V, Roldán V, López-Fernández MF, et al. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost 2010; 8:1012.</a></li><li><a class="nounderline abstract_t">Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86:569.</a></li><li><a class="nounderline abstract_t">Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001; 69:451.</a></li><li><a class="nounderline abstract_t">Penning-van Beest FJ, Geleijnse JM, van Meegen E, et al. Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol 2002; 55:411.</a></li><li><a class="nounderline abstract_t">Visser LE, Penning-van Bees FJ, Kasbergen AA, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88:705.</a></li><li><a class="nounderline abstract_t">Witt DM, Delate T, Clark NP, et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010; 8:744.</a></li><li><a class="nounderline abstract_t">Garcia D, Ageno W, Bussey H, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol 2009; 84:579.</a></li><li><a class="nounderline abstract_t">Nelson WW, Desai S, Damaraju CV, et al. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation. Am J Cardiovasc Drugs 2015; 15:205.</a></li><li><a class="nounderline abstract_t">Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care 2007; 10:1.</a></li><li><a class="nounderline abstract_t">Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006; 5:433.</a></li><li><a class="nounderline abstract_t">Johnson MA. Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K. Nutr Rev 2005; 63:91.</a></li><li class="breakAll">https://ndb.nal.usda.gov/ndb/nutrients/index (Accessed on September 15, 2017).</li><li><a class="nounderline abstract_t">Costa GL, Lamego RM, Colosimo EA, et al. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther 2012; 34:1511.</a></li><li><a class="nounderline abstract_t">Rombouts EK, Rosendaal FR, van der Meer FJ. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 2010; 149:598.</a></li><li><a class="nounderline abstract_t">Sconce E, Khan T, Mason J, et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93:872.</a></li><li><a class="nounderline abstract_t">Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007; 177:369.</a></li><li><a class="nounderline abstract_t">Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm 1998; 55:1581.</a></li><li><a class="nounderline abstract_t">Norwood DA, Parke CK, Rappa LR. A Comprehensive Review of Potential Warfarin-Fruit Interactions. J Pharm Pract 2015; 28:561.</a></li><li><a class="nounderline abstract_t">Srinivas NR. Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives. J Pharm Pharm Sci 2013; 16:289.</a></li><li><a class="nounderline abstract_t">Haber SL, Cauthon KA, Raney EC. Cranberry and warfarin interaction: a case report and review of the literature. Consult Pharm 2012; 27:58.</a></li><li><a class="nounderline abstract_t">Zikria J, Goldman R, Ansell J. Cranberry juice and warfarin: when bad publicity trumps science. Am J Med 2010; 123:384.</a></li><li><a class="nounderline abstract_t">Li Z, Seeram NP, Carpenter CL, et al. Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006; 106:2057.</a></li><li><a class="nounderline abstract_t">Clapauch SH, Benchimol-Barbosa PR. Warfarin resistance and caffeine containing beverages. Int J Cardiol 2012; 156:e4.</a></li><li><a class="nounderline abstract_t">Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8:2182.</a></li><li><a class="nounderline abstract_t">Diug B, Evans S, Lowthian J, et al. The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy. Stroke 2011; 42:2866.</a></li><li><a class="nounderline abstract_t">Levine M, Pizon AF, Padilla-Jones A, Ruha AM. Warfarin overdose: a 25-year experience. J Med Toxicol 2014; 10:156.</a></li><li><a class="nounderline abstract_t">Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood 2018; 132:2230.</a></li><li><a class="nounderline abstract_t">Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177:347.</a></li><li><a class="nounderline abstract_t">Schelleman H, Bilker WB, Brensinger CM, et al. Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010; 123:151.</a></li><li><a class="nounderline abstract_t">Lopes RD, Horowitz JD, Garcia DA, et al. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood 2011; 118:6269.</a></li><li><a class="nounderline abstract_t">Muse O, Patell R, Lee M, et al. Impact of Paxlovid on international normalized ratio among patients on chronic warfarin therapy. Blood 2022; 140:2757.</a></li><li><a class="nounderline abstract_t">Martinelli I, Lensing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127:1417.</a></li><li><a class="nounderline abstract_t">van Dijk KN, Plat AW, van Dijk AA, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 2004; 91:95.</a></li><li><a class="nounderline abstract_t">Knijff-Dutmer EA, Van der Palen J, Schut G, Van de Laar MA. The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM 2003; 96:513.</a></li><li><a class="nounderline abstract_t">Johnson SG, Witt DM, Eddy TR, Delate T. Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. Chest 2007; 131:1500.</a></li><li><a class="nounderline abstract_t">Johnson SG, Rogers K, Delate T, Witt DM. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 2008; 133:948.</a></li><li><a class="nounderline abstract_t">García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123:1108.</a></li><li><a class="nounderline abstract_t">Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68.</a></li><li><a class="nounderline abstract_t">Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797.</a></li><li><a class="nounderline abstract_t">Mahé I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 2005; 59:371.</a></li><li><a class="nounderline abstract_t">Mahé I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica 2006; 91:1621.</a></li><li><a class="nounderline abstract_t">Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy 2007; 27:675.</a></li><li><a class="nounderline abstract_t">Zhang Q, Bal-dit-Sollier C, Drouet L, et al. Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. Eur J Clin Pharmacol 2011; 67:309.</a></li><li><a class="nounderline abstract_t">Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279:657.</a></li><li><a class="nounderline abstract_t">Clark NP, Delate T, Riggs CS, et al. Warfarin interactions with antibiotics in the ambulatory care setting. JAMA Intern Med 2014; 174:409.</a></li><li><a class="nounderline abstract_t">Alexandra JF, Pautas E, Gouin-Thibault I, et al. Overanticoagulation with coumarin and cutaneous azole therapy. Ann Intern Med 2008; 148:633.</a></li><li><a class="nounderline abstract_t">Pottegård A, Henriksen DP, Madsen KG, et al. Change in International Normalized Ratio Among Patients Treated With Dicloxacillin and Vitamin K Antagonists. JAMA 2015; 314:296.</a></li><li><a class="nounderline abstract_t">Fischer HD, Juurlink DN, Mamdani MM, et al. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010; 170:617.</a></li><li><a class="nounderline abstract_t">Mehrotra R, Grover S, Chandra A. Role of World Health Organization Framework Convention on Tobacco Control Global Knowledge Hub on Smokeless Tobacco. Indian J Med Res 2018; 148:7.</a></li><li><a class="nounderline abstract_t">Kuykendall JR, Houle MD, Rhodes RS. Possible warfarin failure due to interaction with smokeless tobacco. Ann Pharmacother 2004; 38:595.</a></li><li><a class="nounderline abstract_t">Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest 2011; 139:1130.</a></li><li><a class="nounderline abstract_t">Nadkarni A, Oldham MA, Howard M, Berenbaum I. Drug-drug interactions between warfarin and psychotropics: updated review of the literature. Pharmacotherapy 2012; 32:932.</a></li><li><a class="nounderline abstract_t">Zierler-Brown SL, Kyle JA. Oral varenicline for smoking cessation. Ann Pharmacother 2007; 41:95.</a></li><li><a class="nounderline abstract_t">Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 2009; 43:1347.</a></li><li><a class="nounderline abstract_t">Damkier P, Lassen D, Christensen MMH, et al. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol 2019; 124:28.</a></li><li><a class="nounderline abstract_t">Greger J, Bates V, Mechtler L, Gengo F. A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents. J Clin Pharmacol 2020; 60:432.</a></li><li><a class="nounderline abstract_t">Cortopassi J. Warfarin dose adjustment required after cannabidiol initiation and titration. Am J Health Syst Pharm 2020; 77:1846.</a></li><li><a class="nounderline abstract_t">Hsu A, Painter NA. Probable Interaction Between Warfarin and Inhaled and Oral Administration of Cannabis. J Pharm Pract 2020; 33:915.</a></li><li><a class="nounderline abstract_t">Brown GW, Bellnier TJ, Janda M, Miskowitz K. Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. J Am Pharm Assoc (2003) 2021; 61:e57.</a></li><li><a class="nounderline abstract_t">La Rosa FG, Clarke SH, Lefkowitz JB. Brodifacoum intoxication with marijuana smoking. Arch Pathol Lab Med 1997; 121:67.</a></li><li><a class="nounderline abstract_t">Roth JA, Bradley K, Thummel KE, et al. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiol Drug Saf 2015; 24:619.</a></li><li><a class="nounderline abstract_t">Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010; 56:823.</a></li><li><a class="nounderline abstract_t">Liu G, Long M, Hu X, et al. Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies. Medicine (Baltimore) 2015; 94:e2233.</a></li><li><a class="nounderline abstract_t">Nelson WW, Desai S, Damaraju CV, et al. International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation. Curr Med Res Opin 2014; 30:2437.</a></li><li><a class="nounderline abstract_t">Witt DM, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114:952.</a></li><li><a class="nounderline abstract_t">Tomisti L, Del Re M, Bartalena L, et al. Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. Endocr Pract 2013; 19:1043.</a></li><li><a class="nounderline abstract_t">van Walraven C, Forster AJ. Anticoagulation control in the peri-hospitalization period. J Gen Intern Med 2007; 22:727.</a></li><li><a class="nounderline abstract_t">Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103:2630.</a></li><li><a class="nounderline abstract_t">D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105:645.</a></li><li><a class="nounderline abstract_t">Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106:2329.</a></li><li><a class="nounderline abstract_t">Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999.</a></li><li><a class="nounderline abstract_t">Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16:101.</a></li><li><a class="nounderline abstract_t">Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112:1022.</a></li><li><a class="nounderline abstract_t">Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784.</a></li><li><a class="nounderline abstract_t">Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106:135.</a></li><li><a class="nounderline abstract_t">Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285.</a></li><li><a class="nounderline abstract_t">Montes R, Ruiz de Gaona E, Martínez-González MA, et al. The c.-1639G &gt; A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006; 133:183.</a></li><li><a class="nounderline abstract_t">Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109:2477.</a></li><li><a class="nounderline abstract_t">Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112:1013.</a></li><li><a class="nounderline abstract_t">Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115:3827.</a></li><li><a class="nounderline abstract_t">O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann N Y Acad Sci 1968; 151:913.</a></li><li><a class="nounderline abstract_t">Alving BM, Strickler MP, Knight RD, et al. Hereditary warfarin resistance. Investigation of a rare phenomenon. Arch Intern Med 1985; 145:499.</a></li><li><a class="nounderline abstract_t">Bodin L, Perdu J, Diry M, et al. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 2008; 6:1436.</a></li><li><a class="nounderline abstract_t">Schmeits PC, Hermans MH, van Geest-Daalderop JH, et al. VKORC1 mutations in patients with partial resistance to phenprocoumon. Br J Haematol 2010; 148:955.</a></li><li><a class="nounderline abstract_t">Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717.</a></li><li><a class="nounderline abstract_t">Leung AY, Chow HC, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001; 98:2584.</a></li><li><a class="nounderline abstract_t">Hermida J, Zarza J, Alberca I, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99:4237.</a></li><li><a class="nounderline abstract_t">Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96:1816.</a></li><li><a class="nounderline abstract_t">Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91:1123.</a></li><li><a class="nounderline abstract_t">Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690.</a></li><li><a class="nounderline abstract_t">Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, et al. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 2004; 75:394.</a></li><li><a class="nounderline abstract_t">Meckley LM, Wittkowsky AK, Rieder MJ, et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100:229.</a></li><li><a class="nounderline abstract_t">Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84:775.</a></li><li><a class="nounderline abstract_t">Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111:4106.</a></li><li><a class="nounderline abstract_t">Pérez-Andreu V, Roldán V, Antón AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113:4977.</a></li><li><a class="nounderline abstract_t">Daneshjou R, Gamazon ER, Burkley B, et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood 2014; 124:2298.</a></li></ol></div><div id="topicVersionRevision">Topic 1337 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574265" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383473" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105637" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227329" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11712286" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010107" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The regulation of hemostasis: the protein C system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010107" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The regulation of hemostasis: the protein C system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333038" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Properties of recombinant human thromboplastin that determine the International Sensitivity Index (ISI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1406880" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906916" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Determinants and measures of quality in oral anticoagulation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18095907" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911722" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systematic overview of warfarin and its drug and food interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19132230" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738136" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27173100" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12888873" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9465843" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315276" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315276" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110451" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3813270" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Resistance to vitamin K antagonists. 6 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8471414" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : High clearance of (S)-warfarin in a warfarin-resistant subject.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8947972" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Warfarin resistance: diagnosis and therapeutic alternatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20149073" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11522005" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11406743" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11927211" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lifestyle and diet as risk factors for overanticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12428081" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20398186" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19610022" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944648" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143047" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dietary vitamin K intake and anticoagulation in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610971" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Warfarin and its interactions with foods, herbs and other dietary supplements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825811" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825811" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22717417" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151978" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886802" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698826" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drug interactions with warfarin: what clinicians need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9706183" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Grapefruit juice and the response to warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25112306" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A Comprehensive Review of Potential Warfarin-Fruit Interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958198" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231999" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cranberry and warfarin interaction: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20399311" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cranberry juice and warfarin: when bad publicity trumps science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17126638" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cranberry does not affect prothrombin time in male subjects on warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21852006" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Warfarin resistance and caffeine containing beverages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20653840" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21836093" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24488527" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Warfarin overdose: a 25-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30463993" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698822" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20103024" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911832" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36240439" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of Paxlovid on international normalized ratio among patients on chronic warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26696010" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14691574" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881594" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494799" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18198244" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Outcomes associated with combined antiplatelet and anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357821" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9987702" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15467911" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15752384" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Paracetamol: a haemorrhagic risk factor in patients on warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145598" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17461702" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21191575" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9496982" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Acetaminophen and other risk factors for excessive warfarin anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24445404" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Warfarin interactions with antibiotics in the ambulatory care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413637" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Overanticoagulation with coumarin and cutaneous azole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26197191" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Change in International Normalized Ratio Among Patients Treated With Dicloxacillin and Vitamin K Antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20386005" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30264749" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Role of World Health Organization Framework Convention on Tobacco Control Global Knowledge Hub on Smokeless Tobacco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14766993" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Possible warfarin failure due to interaction with smokeless tobacco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21540214" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23033232" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Drug-drug interactions between warfarin and psychotropics: updated review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190845" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Oral varenicline for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19531696" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Probable interaction between warfarin and marijuana smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326170" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Interaction between warfarin and cannabis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31724188" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33016308" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Warfarin dose adjustment required after cannabidiol initiation and titration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31319733" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Probable Interaction Between Warfarin and Inhaled and Oral Administration of Cannabis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32828704" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9111096" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Brodifacoum intoxication with marijuana smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25858232" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709439" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Warfarin dosing in patients with impaired kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26683937" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170587" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439733" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Outcomes and predictors of very stable INR control during chronic anticoagulation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23807523" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401605" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Anticoagulation control in the peri-hospitalization period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14656880" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358623" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947090" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322281" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Genetic determinants of response to warfarin during initial anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16424822" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18535201" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574025" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The largest prospective warfarin-treated cohort supports genetic forecasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15790782" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930419" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16611310" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The c.-1639G&gt;A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110455" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18523153" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20203262" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4189970" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Hereditary resistance to coumarin anticoagulant drugs in man and rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977518" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Hereditary warfarin resistance. Investigation of a rare phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18532998" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19961479" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : VKORC1 mutations in patients with partial resistance to phenprocoumon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073515" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11588061" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010835" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961881" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15175798" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Warfarin dosing and cytochrome P450 2C9 polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11926893" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15116052" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Acenocoumarol stabilization is delayed in CYP2C93 carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18690342" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127854" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Genetic modulation of oral anticoagulation with warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250228" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : CYP4F2 genetic variant alters required warfarin dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270263" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25079360" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
